Pulsed Cavitation Ultrasound Softening: a new non-invasive therapeutic approach of calcified bioprosthetic valve stenosis

Brief Title: Non-invasive ultrasound therapy of calcified bioprosthesis

Olivier Villemain, Justine Robin, Alain Bel, Wojciech Kwiecinski, Patrick Bruneval, Bastien Arnal, Mathieu Rémond, Mickael Tanter, Emmanuel Messas, Mathieu Pernot

To cite this version:

<inserm-01675757>

HAL Id: inserm-01675757
http://www.hal.inserm.fr/inserm-01675757
Submitted on 4 Jan 2018

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
MINI-FOCUS: AORTIC VALVE DISEASE

Pulsed Cavitation Ultrasound Softening
A New Noninvasive Therapeutic Approach for Calcified Bioprosthetic Valve Stenosis

Olivier Villemain, MD,a,b Justine Robin, MS,a Alain Bel, MD, c Wojciech Kwiecinski, PhD,a Patrick Bruneval, MD, c Bastien Arnal, PhD,a Mathieu Rémond, PhD, e Mickael Tanter, PhD, a Emmanuel Messas, MD, PhD, b Mathieu Pernot, PhD a

HIGHLIGHTS

- Bioprosthetic heart valves have limited durability, with a progressive deterioration of the bioprosthesis after 12 to 15 years, mainly due to intravalvular calcifications.
- In this proof-of-concept study, we demonstrated in vivo using an ovine model and in vitro that pulsed cavitation focused ultrasound can be used to remotely soften human degenerative calcified bioprosthetic valves and significantly improve the valve opening function.
- This new noninvasive approach has the potential to improve the outcome of patients with severe bioprosthesis stenosis.

From the aInstitut Langevin, Ecole Supérieure de Physique Chimie Industrielles de Paris, Centre National de la Recherche Scientifique, Inserm U979, PSL Research University, Paris, France; bHôpital Européen Georges Pompidou, Université Paris Descartes, Cardio-Vascular Department, UMR 970, Paris, France; cHôpital Européen Georges Pompidou, Cardiovascular Surgery, Université Paris Descartes, Laboratoire de Recherche Biochirurgical, Paris, France; dHôpital Européen Georges Pompidou, Université Paris Descartes, Department of Pathology, Paris, France; and eCardiawave SAS, Paris, France. This work was supported by the LABEX WIFI (Laboratory of Excellence ANR-10-LABX-24) and the French Program “Investments for the Future” under reference ANR-10-IDEX-0001-02 PSL* Research University. Drs. Tanter, Messas, and Pernot are cofounders and shareholders of Cardiawave SAS. Dr. Rémond is an employee of Cardiawave SAS. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Messas and Pernot contributed equally to this work.
**SUMMARY**

The authors propose a novel noninvasive therapeutic approach for degenerative calcified bioprosthetic heart valves based on pulsed cavitational ultrasound (PCU) to improve the valvular function by remotely softening calcified stiff cusps. This study aims to demonstrate both in vivo, using an ovine model with implanted human calcified bioprosthesis, and in vitro that PCU can significantly improve the bioprosthesis function. A 50% decrease of the transvalvular gradient was found, demonstrating a strong improvement of the valve opening function. This new noninvasive approach has the potential to improve the outcomes of patients with severe bioprosthesis stenosis. (J Am Coll Cardiol Basic Trans Science 2017;2:372-83) © 2017 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**METHODS**

**MODEL OF HEART CALCIFIED VALVE.** We used Carpentier-Edwards Perimount Magna (stented bovine pericardial bioprosthesis, Edwards Life sciences, Irvine, California), explanted on a human, as a model of heart calcified valve stenosis. For all patients, the indication of explant was a severe stenosis with calcification. Each valve was fixed in glutaraldehyde 0.6% immediately after explant. Before each experiment, the valve was immersed for 5 min in saline serum (0.9% NaCl) 3 consecutive times. This protocol was in agreement with institutional guidelines (national reference number of the 143 study: 02255.02).

**ULTRASOUND GENERATION AND PCU ACOUSTIC PARAMETERS.** A 1.25-MHz focused single-element transducer (Imasonic, Besançon, France), called a therapy transducer, was used to generate PCU. This transducer had a 100-mm focal length (f-number = 1) and was driven by a high-voltage amplifier (GA-
2500A, RITEC, Warwick, Rhode Island). We produced PCU using 10-cycle pulses, each 8 μs long, delivered at a pulse repetition frequency of 100 Hz. We estimated the pressure peak amplitudes at the focal spot to be 70 and −19 MPa, respectively, for the positive and negative peak pressure.

**ULTRASOUND CAVITATIONAL TREATMENT GUIDANCE AND MONITORING.** Three-dimensional echocardiography was used to guide and monitor the treatment. An IE33 scanner and X5-1 probe (xMATRIX array, 3 MHz, 3,040 elements with microbeam-forming) (Philips Healthcare, Bothell, Washington) were used. The imaging probe was fixed through a hole in the center of the therapy transducer (Figure 1). The focal spot of the therapy transducer was positioned on the central axis of the imaging probe at a depth of 100 mm. A biplane imaging mode with 2 imaging planes set at 90° was used during the entire procedure. The cavitation bubble cloud generated at the PCU focal spot was visible within the 2 imaging planes. The combination of therapy transducer and imaging probe was called the “therapy device.” The same material was used for in vitro and in vivo procedures.

For all the procedures, 10 min sequences of PCU were applied and repeated until the transvalvular gradient was stabilized for 3 consecutive sequences (considered as the ineffective threshold for PCU procedures). The therapy device was controlled by a 3-axis motor to scan the PCU continuously and uniformly over the entire valve.

**SHEAR WAVE ELASTOGRAPHY EVALUATION.** The assessment of valve leaflet biomechanical properties remains challenging and requires destructive strain-stress mechanical tests. To noninvasively assess the modification of the biomechanical properties induced by PCU, we used shear wave elastography, an ultrasound-based tool for noninvasive evaluation of soft tissue’s stiffness. We used the Aixplorer ultrasound imaging system (Aixplorer, Supersonic Imagine, Aix-en-Provence, France) with a linear probe (SL10-2) to evaluate the stiffness of each valvular leaflet. Three acquisitions were made for each leaflet, using the shear wave elastography imaging mode (SWE) of the Aixplorer scanner in the “penetration” setting. A “QBox” region of interest (mean diameter 1 mm) was positioned inside the elasticity image after each acquisition to obtain a mean stiffness value.

**IN VITRO PROCEDURE.** The objective of the in vitro procedure was to analyze the effect of the PCU on the anterograde transvalvular flow, with a pulsatile flow equivalent to the cardiac flow (Figures 2A and 2B). The flow was generated by an artificial heart pump (Pulsatile Blood Pump, Harvard Apparatus, Holliston, Massachusetts) with flow controlled variation. The flow rates were applied at 3, 4, and 5 l/min, and were monitored by a flow sensor (Small Flow Meter Kit, Atlas Scientific, Jacksonville, Florida) (accuracy ± 1 ml/min). The valve and the therapy device were immersed in degassed water. A total of 8 bioprostheses were explanted and used for this procedure. The transvalvular pressure gradient was estimated by:

- A pulsed Doppler ultrasound assessment by applying the Bernoulli equation: \( \Delta P = 4 (V_{\text{max}})^2 \)
- Hemodynamic assessment by pressure sensor before and after the valve (sensor IXIAN 0 to 7.5 PSI Industrial Control Pressure Sensor, Atlas Scientific; accuracy ± 1 mm Hg).

The pump operated during 2 h at a 4 l/min flow rate (70 cycles/min, ejection volume: 57 ml) to control the variation of the gradient before PCU, after which sequences of PCU were applied. All post-PCU transvalvular gradients were reassessed 1 month after the procedure (each valve was fixed in glutaraldehyde between these evaluations). Elastography was performed before and after the procedure on each valve.

Finally, the bioprostheses were sent to the department of pathology for histopathological analysis.

**IN VIVO PROCEDURE: SHEEP MODEL.** The in vivo procedure is shown in Figure 2C. The animal
procedure was approved by the Institutional Animal Care and Use Committee of the Hôpital Européen Georges Pompidou (PARCC) according to the European Commission guiding principles (2010/63/EU).

The sheep were anesthetized with thiopental (0.5 ml/kg), intubated, ventilated at 15 ml/kg with 2% isoflurane, and given glycopyrrolate (0.4 mg intravenous) and vancomycin (0.5 g intravenous). A sterile sternotomy was performed. The calcified bioprosthesis was implanted in the mitral position after CPB. Vital signs (including heart rate, oxygen saturation, and arterial blood pressure), left atrial and ventricle pressure (by 2 Mikro-Tip Millar Catheter Transducers, to have the transvalvular pressure gradient in real time), and cardiac flow (by a Swan-Ganz CCOMbo Pulmonary Artery Catheter, Edwards Lifesciences) were monitored. The CPB was stopped and removed to restore independent cardiac activity. Sternotomy was maintained and the thorax was filled with degassed saline water. A complete echocardiography was performed, especially to evaluate the calcified bioprosthesis (12–14). A total of 14 explanted bioprostheses were used for this procedure.

We then applied the sequences of PCU. An echocardiographic evaluation was performed between each 10-min sequence, concurrent with the catheter’s evaluation (pressure and cardiac flow).

At the end of the procedure, the animal was sacrificed (Dolethal intravenous injection, 1 ml/kg) and an anatomic macroscopic evaluation of the cardiac structure was performed. Elastography examination of the bioprosthesis was performed before and after each procedure. The bioprosthesis was then explanted and sent after elastography to the department of pathology for histopathological analysis.

**MICROSCOPIC ANALYSIS. Histological exploration.** Immediately after the procedure (in vitro and in vivo), the bioprosthesis was dissected, fixed in formalin, and embedded in individual paraffin blocks. Regions of interest, such as macroscopic calcification on leaflet, were labelled with tattoo ink. Serial sections were stained with hematoxylin and eosin for histopathological analysis.

In addition, we also analyzed 5 calcified bioprostheses directly after their explantation from humans, without any PCU procedure. The objective was to perform a histopathological comparison between bioprostheses with or without PCU.

**Micro-computed tomography imaging.** The micro-computed tomography (CT) device used in this study was the Quantum FX Caliper (Life Sciences, Perkin Elmer, Waltham, Massachusetts). Samples up to a 10-mm diameter field of view and 3-dimensional acquisitions were performed using an isotropic voxel size of $20 \times 20 \times 20 \mu m^3$. Full 3-dimensional, high-resolution raw data were obtained by rotating both the x-ray source and the flat panel detector $360^\circ$ around the sample, with a rotation step of 0.1°. The corresponding 3,600 image projections were then automatically reconstructed (RigakuSW software, Caliper, Newton, Massachusetts) into a DICOM (Digital Imaging and Communications in Medicine) stack of 512 files, using standard back-projection techniques.
STATISTICAL ANALYSIS. Continuous variables were presented as mean ± SD. A Wilcoxon matched-pairs signed-ranks test was performed to evaluate the SD between individual mean values before and after therapy. The level of significance was set at an alpha level of ≤0.05. The analysis was conducted using MedCalc software (version 14.10.2, MedCalc, Mariakerke, Belgium).

### TABLE 1 In Vivo Results

<table>
<thead>
<tr>
<th></th>
<th>Before Therapy</th>
<th>After Therapy</th>
<th>Variation (%)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shear wave imaging</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elastography (kPa)</td>
<td>76.1 ± 23.7</td>
<td>35.6 ± 7.2</td>
<td>-52 ± 7</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Echocardiography</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doppler mitral valve (Figure 5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximal velocity, m/s</td>
<td>2.41 ± 0.50</td>
<td>1.73 ± 0.21</td>
<td>-28 ± 6</td>
<td>0.0007</td>
</tr>
<tr>
<td>Maximal pressure gradient, mm Hg</td>
<td>24.0 ± 4.4</td>
<td>12.1 ± 1.4</td>
<td>-49 ± 11</td>
<td>0.0003</td>
</tr>
<tr>
<td>Mean velocity, m/s</td>
<td>1.95 ± 0.36</td>
<td>1.38 ± 0.24</td>
<td>-29 ± 6</td>
<td>0.0001</td>
</tr>
<tr>
<td>Mean pressure gradient, mm Hg</td>
<td>16.2 ± 3.2</td>
<td>8.2 ± 1.3</td>
<td>-48 ± 7</td>
<td>0.0001</td>
</tr>
<tr>
<td>Mitral valve area, cm²</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By pressure half time (Figure 5)</td>
<td>1.09 ± 0.09</td>
<td>1.57 ± 0.08</td>
<td>+143 ± 18</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>By continuity equation</td>
<td>1.10 ± 0.15</td>
<td>1.58 ± 0.15</td>
<td>+142 ± 15</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>By planimetry (Figure 5)</td>
<td>1.13 ± 0.13</td>
<td>1.54 ± 0.14</td>
<td>+137 ± 14</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pulmonary artery pressure, mm Hg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximal (tricuspid valve)</td>
<td>64.7 ± 12.8</td>
<td>34.1 ± 10.2</td>
<td>-47 ± 12</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Cardiac output, L/min</td>
<td>2.98 ± 0.10</td>
<td>2.96 ± 0.14</td>
<td>-1.0 ± 0.2</td>
<td>0.83</td>
</tr>
<tr>
<td>Pressure sensors (Millar), mm Hg</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean diastolic LAP</td>
<td>36.8 ± 6.2</td>
<td>20.2 ± 5.1</td>
<td>-44 ± 11</td>
<td>0.0004</td>
</tr>
<tr>
<td>Mean diastolic LVP</td>
<td>17.4 ± 2.7</td>
<td>11.4 ± 1.9</td>
<td>-35 ± 10</td>
<td>0.0014</td>
</tr>
<tr>
<td>Mean diastolic gradient LVP-LAP</td>
<td>17.4 ± 2.4</td>
<td>8.8 ± 1.2</td>
<td>-50 ± 13</td>
<td>0.0002</td>
</tr>
<tr>
<td>Cardiac output (L/min)</td>
<td>2.87 ± 0.11</td>
<td>2.96 ± 0.14</td>
<td>+3.0 ± 0.4</td>
<td>0.74</td>
</tr>
</tbody>
</table>

Values are mean ± SD. *Variation = (Result after - result before)/result before × 100. †Cardiac output = HR × LVOT area × LVOT VTI.

RESULTS

All of our results consistently showed a softening of the valve leaflets, allowing a decrease of the anterograde gradient after PCU. This decrease persisted 1 month after the procedure. The decrease of transvalvular gradient measured by Doppler echocardiography was confirmed by invasive pressure sensors in both the in vitro and in vivo setup.

**IN VITRO PROCEDURE.** Eight bioprosthesis were explanted and used for the in vitro procedure (Figure 3). At a flow rate of 4 l/min, the mean transvalvular gradient over the set of valves was 21.1 ± 3.9 mm Hg (maximum 38 mm Hg, minimum 10 mm Hg) (Figure 3), and the maximum gradient was 39 ± 6.9 mm Hg (maximum 73 mm Hg, minimum 22 mm Hg). After 2 h of controlled pulsatile flow without PCU, we observed no statistically significant change of the transvalvular gradients. The mean duration of PCU was 70 ± 12 min with a maximum duration of 90 min and a minimum of 50 min. After the procedure, the mean transvalvular gradient was 9.6 ± 1.7 mm Hg (maximum 19 mm Hg; minimum 4 mm Hg), corresponding to a decrease of 55 ± 10% (p < 0.001). The maximum gradient was 19.6 ± 3.5 mm Hg (maximum 37 mm Hg; minimum 10 mm Hg), corresponding to a decrease of 51 ± 9% (p < 0.001). The results of each individual bioprosthesis are shown in Supplemental Figure 1.

Hemodynamic parameters were also measured at 3 and 5 l/min before and after procedure. The gradients also showed a significant decrease at the different flow rates (p < 0.001) (Supplemental Figure 2). At 3 l/min, the mean gradient varied from 14.2 ± 2.5 mm Hg to 7.1 ± 1.2 mm Hg (p < 0.001) and the maximum gradient from 29.1 ± 5.1 mm Hg to 14.9 ± 2.6 mm Hg (p < 0.001). At 5 l/min, the mean gradient varied from 23.8 ± 4.2 mm Hg to 13.0 ± 2.3 mm Hg (p < 0.001) and the maximum gradient from 42.3 ± 7.5 mm Hg to 24.1 ± 4.3 mm Hg (p < 0.001).

The gradient dependence with flow rate allowed us to assess the pliability of the valve cusps before and after the procedure. Pliability is indeed inversely linked to the slope of the gradient-flow rate relationship. The slope of the maximum gradient-flow rate relationship was found to decrease from 9 ± 4.3 mm Hg/l/min to 4.9 ± 2.9 mm Hg/l/min (p < 0.001), which confirmed an improved pliability of the valve cusps after the procedure.

All post-PCU transvalvular gradients were reassessed 1 month after the procedure, and no statistically significant difference was observed (Figure 3).
**IN VIVO PROCEDURE.** Fourteen explanted biopros-
thesis were used for this procedure (Table 1, Figures 4 and 5, Supplemental Video 1). A total of 7 animals
experienced a massive acute pulmonary edema with
severe heart failure just after the implantation of the
valve and the cessation of the CPB. These animals
died before the PCU procedure. The other animals
tolerated the implantation. Thus, 7 valves were treated
and analyzed. The mean weight of the animals was
37.8 ± 4.6 kg (minimum 29 kg; maximum 43 kg).

Just after the valve implantation, we monitored all
parameters for 1 h before any PCU procedure. From
the beginning (just after the valve implantation) to 1 h
after implantation (before any PCU procedure), there
was no statistical significant difference of the trans-
valvular gradients ($p = 0.45$) and mitral valve areas

---

**FIGURE 4 Images of Echocardiography During Procedure**

<table>
<thead>
<tr>
<th>Long Axis</th>
<th>Doppler</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Before Therapy</strong></td>
<td><img src="image1" alt="Echocardiography Before Therapy" /></td>
</tr>
<tr>
<td><strong>During Therapy</strong></td>
<td><img src="image2" alt="Echocardiography During Therapy" /></td>
</tr>
<tr>
<td><strong>After Therapy</strong></td>
<td><img src="image3" alt="Echocardiography After Therapy" /></td>
</tr>
</tbody>
</table>

During PCU a “cavitation bubble cloud” is visible as a hyperechogenic zone (red arrow). After PCU, the improvement of the bioprosthesis opening is confirmed thanks to the echocardiography (green arrow). The images are realized during diastasis (closed aortic valve). See Supplemental Video 1. Ao = aorta; other abbreviations as in Figure 2.
The mean procedure duration was 60 ± 13 min (maximum 100 min; minimum 40 min) (see Supplemental Video 1 of an in vivo procedure). We observed an important decrease of the transvalvular gradient after PCU (Table 1), which was on average reduced by 50%. The results of elastography, echocardiography, and of pressure/flow cardiac catheters after the PCU procedures are synthesized in Table 1. The mean cardiac frequency was 123 ± 9 (minimum 94; maximum 154), and all hemodynamic parameters were stable during the procedures: heart rate (p = 0.24), blood pressure (p = 0.27), and O₂ saturation (p = 0.42).

No mitral valve regurgitation was observed at the end of the procedures.

We observed isolated ventricular extrasystoles in 2 animals, without any repercussion in hemodynamic parameters. As long as the focal spot of the therapy device remained on the bioprosthesis, no arrhythmia was visible.

After the threshold was reached and all parameters were re-evaluated, the animal was sacrificed and the heart was explanted. Macroscopic analysis showed that all cardiac structures were intact (Figure 6), except in 1 animal in which a 7-mm diameter superficial hematoma (epicardium) was visible at the lateral left ventricle wall (on the path of the ultrasound beam). This animal was also 1 of 2 animals that presented isolated ventricular extrasystoles. At the end of the procedure, the bioprosthesis was sent to the department of pathology for histopathological analysis.
ELASTOGRAPHY. Elastography results are displayed in Figures 7A and 7B. In vitro, before PCU, the mean stiffness of the valve leaflets measured by elastography was 105.8 ± 9 kPa. After the procedure, the mean stiffness of the valve leaflets measured by elastography was 46.6 ± 4 kPa, corresponding to a decrease of 55 ± 8% (p < 0.001).

We observed a similar stiffness decrease for the bioprosthesis used in vivo (82.6 ± 10 kPa before the procedure and 41.7 ± 7 kPa after PCU, 49 ± 7% decrease; p < 0.001). The results of each individual bioprosthesis are shown in Supplemental Figure 3.

MICROSCOPIC ANALYSIS. Histological exploration. The histological exploration is described in Figure 8. All superficial structures of the leaflets were intact (fibrosa and ventricularis). In comparison with the 5 bioprosthesis explanted without PCU procedure, we observed:

- A fragmentation of the calcification.
- Presence of vacuoles inside the calcification.

There was no histological evidence for acute inflammation or acute thrombosis on the bioprosthesis.

Micro-CT imaging. Micro-CT imaging did not show modifications of the calcification shapes (Supplemental Figure 4). However, we did observe qualitatively multiple fragmentations inside of the calcification after PCU. These micro-fragmentations are visible as subvoxel modifications of the CT image (size <20 μm) so that quantitative analysis remains limited.

The estimation of calcification volume shows no statistical difference before PCU (mean volume = 294.9 mm³ [minimum 45.7 mm³; maximum 662.3 mm³]) and after PCU (mean volume = 288.9 mm³ [minimum 42.9 mm³; maximum 659.9 mm³]), with a mean diminution of 2.02% (p = 0.44).

DISCUSSION

In this study, we demonstrated in vitro and in vivo that PCU can remotely decrease the transvalvular gradients of calcified bioprothetic valves. The mean and maximal transvalvular gradients decreased by 2-fold on average in both the in vitro and in vivo setups. Moreover, these hemodynamic modifications persisted after 1 month (evaluated only in vitro). The evolution of other echocardiographic parameters measured in vivo (valve area, pulmonary artery pressure) confirmed a consistent decrease of the valvular stenosis. Finally, we showed that PCU induced a decrease of the valves leaflet stiffness.

We believe that PCU can have a real clinical effect on the treatment of calcified bioprosthesis stenosis. Its 2 main advantages are: 1) it could be potentially applied in a transthoracic configuration completely noninvasively; and 2) it would allow the preservation of the bioprosthesis valve ad integrum.

EFFECT OF PCU ON CALCIFIED BIOPROSTHESIS VALVE. Using quantitative shear wave elastography, we demonstrated that the biomechanical properties of calcified leaflets were modified by PCU. The stiffness was decreased on average by 2-fold. The softening mechanism induced by PCU may be complex and needs to be further investigated; however, we can hypothesize that calcifications are mostly affected by the treatment. The histological analyses showed a fragmentation of calcifications with the preservation of the leaflet superficial structures. Micro-CT imaging, which can be considered a gold standard for valvular calcification evaluation (15,16), confirmed that microfragmentations appeared inside the calcification after PCU. This microfragmentation of large calcifications could explain the overall change of biomechanical properties, which leads to the improvement of the leaflet motion. Further investigation is required to better understand other potential mechanisms of PCU and, in particular, its effect on soft valvular tissues.
**SAFETY. Accuracy of therapy.** For 2 animals, we observed a few nonpersistent ventricular extrasystoles, and post-mortem anatomic exploration showed bruising of the cardiac wall due to off-target cavitation. These 2 undesirable effects are mostly induced by the actual complexity of the target positioning and motion, and could be greatly reduced with some technical improvements. As our therapeutic transducer is readily focused at a single location, the target position can only be changed by mechanically and slowly moving the therapy device with millimetric motors. To solve this problem, a multielement transducer could be used to steer the focal spot electronically in real time. Three-dimensional motion correction would then be feasible in real-time, based on an accurate ultrasonic speckle-tracking method that has been demonstrated for high-intensity focused ultrasound applications in 2004 by our team (17) and, more recently, for histotripsy (18). With such a motion correction technique, we would be able to track the valve motion all along the cardiac cycle and avoid off-target cavitation. An easier strategy would be to trigger PCU exposures by electrocardiogram (19). We could, for instance, select specific moments in the cardiac cycle when the valve is closed. Thus, its whole surface would be equally exposed and far away from the cardiac wall.

**Emboli.** Our study aimed to demonstrate proof of concept of efficacy. We have thus not precisely evaluated the clinical risk of emboli during and after PCU by endovascular filter or brain magnetic resonance imaging/CT, and these explorations should be performed during specific risk evaluation studies. Nevertheless, our histological exploration after in vitro and in vivo procedures have shown the preservation of the leaflet superficial structures (fibrosa and ventricularis). These are fundamental structures around the calcification (20), meaning that our action seems to be confined within the leaflet. This result was confirmed by the micro-CT explorations, which found no statistical difference in calcification volumes before and after PCU. This local intravalvular effect is a reassuring argument against the major risk of emboli. Moreover, the specific
Histological lesions due to PCU noted inside the calcification (vacuole) seem to preserve the overall architecture of the valve leaflet.

Concerning cardiac application of PCU, in 2009, Xu et al. (21) showed that the size of myocardium debris obtained after histotripsy was inferior to the size of a red blood cell for >99% of the debris. As of now, no studies have been conducted specifically on valvular calcifications and PCU.

**STUDY LIMITATIONS.** In vivo follow-up. We observed stability of the transvalvular gradient in vitro 1 month after the procedure. However, this was not confirmed for the in vivo procedure, because we sacrificed the animals directly after the procedure. It is, therefore, difficult to evaluate the persistence of the therapeutic effect.

Shear wave elastography evaluation. Shear wave elastography has never been used for the stiffness evaluation of valve leaflets; therefore, this application needs to be validated in further studies. In particular, previous studies have shown the limitation of shear wave elastography in thin layers such as in the arterial wall. In such a medium, the shear waves are guided inside the 2-dimensional leaflet, and correspond to leaky lamb wave propagation (22). This affects the elastography measures, which prohibits direct derivation of the absolute values of leaflet stiffness. Nevertheless, semiquantitative evaluation of leaflet stiffness remains possible by performing elastography before and after PCU on the same leaflet (22,23).

**Transthoracic approach.** Transthoracic treatment should be feasible but requires further development of the therapy device. The main challenge of the transthoracic approach is to overcome the effect of the deep heterogeneous tissue layers on the path of the ultrasound beam. The ribs are a particularly strong barrier for ultrasound, allowing the ultrasonic beam to propagate only through the intercostal space. This limited aperture reduces the energy at the focal point as well as the quality of the focus. However, previous work in the field of histotripsy (24,25) and high-intensity focused ultrasound (26) have shown the feasibility of transcostal focusing.

**CLINICAL APPLICATIONS.** The treatment of calcified bioprosthesis stenosis in the mitral or aortic position is currently still a challenge. Redo surgery or
transapical transcatheter valve-in-valve implantation expose the patient to significant risks, especially for patients with comorbidities (5,27). The results presented in this study may provide a new treatment option for these patients. From a general point of view, the PCU could be applied to a calcified bioprosthesis whatever its localization (aortic, mitral, tricuspid, or pulmonary), and this should be confirmed in further animal and human studies. If these results are confirmed and stable in the long-term, the indication of bioprosthesis could be expanded to a wider and younger population with the acceptable perspective of noninvasive redux therapy in the long-term. This application, however, still needs to be confirmed by further prospective studies and significant follow-up.

CONCLUSIONS

We have demonstrated in vitro and in vivo that PCU can significantly decrease the transvalvular gradient of a calcified bioprosthesis stenosis by softening the leaflets remotely and improving valve opening. We believe that this novel ultrasound therapy could become a noninvasive therapeutic strategy in cardiology. This new noninvasive approach has the potential to improve the outcome of patients with severe calcified bioprosthesis stenosis by avoiding risky surgical or transcatheter reintervention.

ACKNOWLEDGMENTS The authors thank Hicham Serroune (Institut Langevin), Julie Piquet, and the staff of the Fondation Alain Carpentier and the Laboratoire biochirurgical.

REFERENCES


PERSPECTIVES

COMPETENCY IN MEDICAL KNOWLEDGE: Heart valves are being increasingly replaced by bioprostheses. These bioprostheses have a limited lifespan, and degenerative calcified bioprosthesis carries a dire prognosis despite recent advances in surgery and transcatheter valve-in-valve implantation. Less-invasive strategies to treat calcified valves are needed. The results of this study show that PCU can soften calcified leaflets noninvasively and improve their opening function.

TRANSLATIONAL OUTLOOK: The present study is a proof of concept of the efficacy of PCU to soften bioprosthesis valves. This is an important initial step in translating PCU softening toward clinical applications. Future experimental and translational studies are required to investigate the feasibility and the safety of this new therapeutic approach in human patients.

ADDRESS FOR CORRESPONDENCE: Dr. Emmanuel Messas, Hôpital Européen Georges Pompidou, Cardio-vascular Department Faculté de médecine Paris Descartes, Université Paris Descartes Inserm UMR 970 Paris Research Cardiovascular Center. Paris, Ile-de-France 75908, France. E-mail: emmanuel.messas@aphp.fr.


KEY WORDS bioprosthesis, therapy, ultrasonic

APPENDIX For supplemental figures and a video, please see the online version of this article.